Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7688297
Reference Type
Journal Article
Title
Management of patent ductus arteriosus in premature infants
Author(s)
Bhat, R; Das, UG; ,
Year
2015
Is Peer Reviewed?
Yes
Journal
Indian Journal of Pediatrics
ISSN:
0019-5456
EISSN:
0973-7693
Publisher
SPRINGER INDIA
Location
NEW DELHI
Volume
82
Issue
1
Page Numbers
53-60
Language
English
PMID
25532746
DOI
10.1007/s12098-014-1646-6
Web of Science Id
WOS:000351564100012
URL
http://link.springer.com/10.1007/s12098-014-1646-6
Exit
Abstract
Patency of the ductus arteriosus is required for fetal survival in utero. In infants born prematurely, ductus fails to close and shunt reverses from left to right. Incidence of patent ductus arteriosus (PDA) is inversely proportional to the gestational age. A large PDA (>1.5 mm diameter) with left to right shunt in very low birth weight infants can cause pulmonary edema, congestive heart failure, pulmonary hemorrhage and increase the risk for bronchopulmonary dysplasia. Attempts to prevent or close the duct by pharmacological or surgical methods have not changed the morbidity or the long term outcome. Pharmacological treatment with indomethacin or ibuprofen is successful in 75 to 80 % of infants but its use also exposes these infants to undesirable side effects like gastrointestinal bleeding, perforation and necrotizing enterocolitis. Prophylactic therapy with indomethacin or ibuprofen to prevent PDA has not altered the morbidity or long term outcome. Currently, there is a dilemma as to how to treat, when to treat and whom to treat. Recent literature suggests a trial of conservative management during the first week followed by selective use of anti-inflammatory drugs. Surgical ligation is reserved for infants who fail medical therapy and still remain symptomatic. Spontaneous closure of the PDA has been reported in up to 40-67 % of very low birth weight (VLBW) infants by 7 d. In this review authors discuss these controversies and propose a more rational approach.
Keywords
BNP: Brain natriuretic peptide; hsPDA: Hemodynamically significant PDA; NSAID: Non-steroidal anti inflammatory drugs; NT pro BNP: N-terminal-pro-B natriuretic peptide; TnT: Troponin T; VEGF: Vascular endothelial growth factor; VLBW: Very low birth weight
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity